Moomoo AI 已提取核心信息
CRISPR Therapeutics AG, a biotechnology company, was the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission. The amendment, filed on February 5, 2024, indicates that Sumitomo Mitsui Trust Holdings, Inc. (SMTH) and Nikko Asset Management Co., Ltd. (NAM), both based in Japan, have reported shared voting and dispositive power over 3,369,762 common shares of CRISPR Therapeutics, representing 4.24% of the class. The filing was made under Rule 13d-1(b), with both SMTH and NAM classified as parent holding companies and NAM additionally as an investment adviser. The shares are beneficially owned by their subsidiary, Nikko Asset Management Americas, Inc. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of CRISPR Therapeutics.
CRISPR Therapeutics AG, a biotechnology company, was the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission. The amendment, filed on February 5, 2024, indicates that Sumitomo Mitsui Trust Holdings, Inc. (SMTH) and Nikko Asset Management Co., Ltd. (NAM), both based in Japan, have reported shared voting and dispositive power over 3,369,762 common shares of CRISPR Therapeutics, representing 4.24% of the class. The filing was made under Rule 13d-1(b), with both SMTH and NAM classified as parent holding companies and NAM additionally as an investment adviser. The shares are beneficially owned by their subsidiary, Nikko Asset Management Americas, Inc. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of CRISPR Therapeutics.
生物技术公司CRISPR Therapeutics AG是最近向美国证券交易委员会提交的附表13G/A文件的主题。该修正案于2024年2月5日提交，表明总部位于日本的三井住友信托控股有限公司（SMTH）和日兴资产管理有限公司（NAM）已报告了对CRISPR Therapeutics的3,369,762股普通股的共享投票权和处置权，占该类别的4.24％。该文件是根据第13d-1（b）条提交的，SMTH和NAM均被归类为母控股公司，NAM另外被归类为投资顾问。这些股份由其子公司日兴资产管理美洲公司实益持有。该文件称，这些股份是在正常业务过程中收购的，不是为了改变或影响CRISPR Therapeutics的控制权。
生物技术公司CRISPR Therapeutics AG是最近向美国证券交易委员会提交的附表13G/A文件的主题。该修正案于2024年2月5日提交，表明总部位于日本的三井住友信托控股有限公司（SMTH）和日兴资产管理有限公司（NAM）已报告了对CRISPR Therapeutics的3,369,762股普通股的共享投票权和处置权，占该类别的4.24％。该文件是根据第13d-1（b）条提交的，SMTH和NAM均被归类为母控股公司，NAM另外被归类为投资顾问。这些股份由其子公司日兴资产管理美洲公司实益持有。该文件称，这些股份是在正常业务过程中收购的，不是为了改变或影响CRISPR Therapeutics的控制权。
有用
没用